Redasemtide misses Phase 2b stroke endpoint, Shionogi reports

Shionogi announced on September 9 that redasemtide, an investigational peptide licensed from StemRIM, missed the primary endpoint in a global Phase 2b trial for acute ischemic stroke. The result leaves its potential to improve recovery after stroke unresolved, a clinically important question for preserving function and independence.

The company also reported ulcer closure in three of four patients in a separate Phase 2 study involving dystrophic epidermolysis bullosa. Those findings concern a different disease and cannot establish that the peptide improves neurological recovery.

### What the stroke trial tested

The REvive study, registered as NCT05953480, was a multinational, randomized, double-blind comparison of redasemtide and placebo in adults with acute ischemic stroke. The ClinicalTrials.gov record lists 680 participants overall; that number should not be read as the size of the particular cohort behind the announced primary analysis.

The registry describes two cohorts distinguished by eligibility for, or receipt of, treatments that restore blood flow. These include systemic thrombolysis, which dissolves clots, and mechanical recanalization, which reopens blocked vessels. Separating these populations matters because their accompanying treatments and recovery prospects may differ.

The UK Health Research Authority’s earlier study summary explains the original rationale: testing a potential treatment for patients unable to receive clot-dissolving therapy or thrombectomy. It describes ischemic stroke as a sudden interruption of blood flow to part of the brain that causes loss of neurological function. A therapy that improves subsequent recovery could therefore address a meaningful source of lasting disability.

Shionogi identified the primary outcome as the modified Rankin Scale at 90 days in the cohort without endovascular recanalization therapy. This assesses disability after stroke. The company reported no statistically significant improvement over placebo.

### Exploratory signals leave questions open

Shionogi highlighted an exploratory trend among patients with greater initial stroke severity. Such a finding can help generate a hypothesis for another trial, but it cannot substitute for success on the primary endpoint.

The distinction is consequential. A primary endpoint defines the main question a trial is intended to answer. Looking within smaller groups afterward may reveal useful patterns, but those patterns require scrutiny of how the groups were defined, how many comparisons were made, and whether the apparent differences are reliable.

The announcement did not provide the treatment effect, confidence interval, or detailed outcome distribution needed to assess the magnitude and precision of the stroke result. A nonsignificant comparison does not establish that the treatments are equivalent; equally, an improvement described as a trend does not establish clinical benefit.

### Separate findings, separate evidence standards

Redasemtide is derived from the protein HMGB1. Its development across different conditions does not make efficacy transferable between them. The four-patient skin-disease finding is especially vulnerable to uncertainty from the tiny sample, and the announcement alone cannot establish the durability or comparative benefit of ulcer closure.

Shionogi reported no new safety concerns and said it would analyze the stroke findings before deciding its development direction. That preliminary safety assessment should not be treated as a comprehensive safety conclusion without detailed adverse-event data.

For readers following peptide therapeutics, the practical meaning is a limit on the current evidence: this study has not established improved post-stroke function. Full results are needed to understand whether further development has a defensible clinical rationale. Neither the exploratory stroke signal nor the separate skin finding establishes a general regenerative or longevity benefit.